Autolus Therapeutics plc

AUTL Q1 2026

Reported: 2026-05-18

Shares fell 4.7% after earnings despite an unchanged full-year revenue outlook, reflecting investor concern about slowing growth momentum and cautious incremental progress during the commercial launch phase.

Key takeaways

Q1 revenue of $26.2 million, with unchanged 2026 full-year guidance of $120 million to $135 million.
First quarter showing positive gross margin, attributed to operational efficiencies and increased volume at the manufacturing plant.
Early U.S. and U.K. commercial launches progressing with 73 U.S. centers active, expected to exceed 80 by year-end; over 10 centers active in the U.K. under NHS access.
Product optimization efforts include a 13% workforce reduction aimed at improving cost structure, targeting a peak gross margin of 65-70% for the core ALL business.
Pipeline progress continues with pediatric Phase II expansion underway and data expected near end of 2027; FDA alignment on protocol for registration.

View recap

Avax One Technology Ltd

AVX Q1 2026

Reported: 2026-05-18

Avax One’s Q1 results prompted a muted market reaction of +0.6%, reflecting a largely in-line performance as the company's strategic evolution into AI and digital infrastructure progresses without clear near-term inflection in revenue or margin trends.

Key takeaways

The company is pivoting toward behind-the-meter AI and high-performance computing infrastructure, targeting modular power solutions in energy advantage regions.
Progress continues on a 10-megawatt Tier 3-ready critical power facility in Alberta, with engineering moving into detailed design phases and on track for Q1 2027 readiness.
The Avalanche treasury strategy remains a strategic asset, with Avalanche blockchain adoption gaining institutional and public sector traction, supporting long-term optionality.
Operational expertise in power-intensive markets like Alberta and Ohio underpins the transition, though immediate financial impacts or guidance shifts were not highlighted.
Market reaction suggests investors are reserving judgment pending further execution and financial clarity on the infrastructure pivot.

View recap

Beam Global

BEEM Q1 2026

Reported: 2026-05-18

Shares dropped 6.5% after results disappointed investors due to a steep 51% revenue decline driven by order timing issues and a cautious outlook amid geopolitical disruption. Gross margin compression and ongoing net losses despite cost controls also weighed on sentiment.

Key takeaways

Q1 2026 revenue fell 51% year-over-year to $3.1 million, chiefly due to two large EV ARC orders deferred to Q2, seasonal softness in Europe, and reduced federal EV spending.
Gross margin declined sharply, with an adjusted non-GAAP gross margin of 9.4% versus 20.6% a year ago, impacted by fixed overhead on lower volumes.
Net loss improved nominally from $15.5 million to $6.9 million but included $3.5 million in noncash charges; adjusted net loss widened slightly to $3.7 million from $3 million.
Operationally, backlog increased 50% sequentially to $9 million, and early Q2 revenue bookings already exceed Q1, signalling potential acceleration.
Geopolitical headwinds in the Middle East dampened near-term momentum, but management highlighted ongoing strategic initiatives and first sales in new markets like Abu Dhabi.

View recap

Engine Gaming and Media, Inc.

GAME Q1 2026

Reported: 2026-05-18

GameSquare’s shares fell 15.2% following earnings as investors reacted negatively to a cautious outlook and a persistent adjusted EBITDA loss, signaling concerns around profitability despite revenue growth and recent acquisitions.

Key takeaways

Revenue nearly doubled year-over-year, increasing by 95%, supported by the integration of recent acquisitions Click and TubeBuddy.
Gross profit expanded by approximately 77%, adding $2.4 million, reflecting scale gains within the business.
Adjusted EBITDA loss remained at $656,000, consistent with management’s seasonal expectations but still negative, underscoring ongoing profitability challenges.
The GameSquare Experiences division (GSX) achieved record bookings exceeding $10 million in Q1, driven by large video game publishers and global brand demand.
Despite operational progress and platform momentum, the market reaction suggests investor skepticism about the company’s path to sustained profitability and growth execution.

View recap

Genmab A/S

GMAB.CO Q1 2026

Reported: 2026-05-18

Genmab’s Q1 2026 results were largely in line with expectations, as reflected by the modest 0.4% stock reaction, with solid revenue growth balanced against ongoing heavy investment and no changes to guidance.

Key takeaways

Total revenue grew 25% year-over-year, driven by strong momentum across the portfolio.
Proprietary product sales rose 43%, led by EPKINLY’s 52% growth ($137 million), benefiting from label expansion and removal of post-dose hospitalization recommendation.
Tivdak sales increased 18% to $39 million, maintaining its leadership in recurrent/metastatic cervical cancer.
The Phase III RAINFOL-02 trial for Rina-S completed enrollment ahead of schedule, setting the stage for pivotal data in H2 2026.
Management maintained full-year guidance and reiterated 2026 as a catalyst-rich year, though no incremental positive surprises or upgrades were announced.

View recap

Klarna Group plc

KLAR Q1 2026

Reported: 2026-05-18

Klarna reported solid topline growth and margin expansion in Q1 2026, but the market's neutral reaction reflects tempered investor enthusiasm amid ongoing margin pressures and cautious outlook dynamics.

Key takeaways

Revenue increased 44% year-over-year to $1.012 billion, driven by a 33% GMV growth to $33.7 billion.
Transaction margin dollars rose 44% to $389 million, demonstrating healthy operating leverage as non-transaction costs grew only 3%.
Adjusted operating income improved to $68 million from $3 million a year ago; net income turned positive at $1 million but EPS remained slightly negative at -$0.01 due to capital bond interest.
Provision for credit losses declined sequentially to $186 million (55 bps of GMV), reflecting maturation of Fair Financing but continued elevated transaction and servicing costs, which grew 62%, signaling margin pressure from growth investments.
The company reiterated full-year guidance and highlighted strategic focus areas: default PSP expansion, spend-centric product mix, and deposit-funded origination growth.

View recap

Lument Finance Trust, Inc.

LFT Q1 2026

Reported: 2026-05-18

Shares fell 7.0% as investors reacted negatively to a cautious outlook and margin pressure amid uneven CRE recovery and increased reserves on legacy assets, signaling limits to near-term growth and profitability.

Key takeaways

Reported a GAAP net loss of $0.02 per share and distributable earnings of $0.02 per share, reflecting minimal profitability.
Maintained the quarterly dividend at $0.04 per share despite weak earnings.
Credit performance remained stable overall, but management increased reserves on certain legacy positions, indicating recognition of persistent risks.
Portfolio activity included $47 million of payoffs, offset by reinvestments in two new multifamily loans totaling $48 million, showing cautious capital redeployment.
Management highlighted continued uncertainty in CRE markets, with selective financing and widening performance disparities by asset quality and location weighing on outlook.

View recap

PAVmed Inc.

PAVM Q1 2026

Reported: 2026-05-18

PAVmed shares fell 3.7% following the earnings release, reflecting investor disappointment with continued delays in key commercial milestones and a cautious near-term outlook despite ongoing pipeline progress.

Key takeaways

The company completed a capital structure cleanup, positioning for future growth, but no near-term revenue inflection was evident.
Lucid Diagnostics remains a major focus, with Medicare coverage still delayed, maintaining uncertainty around significant revenue catalysts.
Initial traction with the Veterans Administration and positive payer coverage offer some upside but have yet to drive meaningful volume or cash flow.
Veris is progressing through clinical rollout and product development but remains in early commercialization with ongoing R&D spending on implantable devices and AI projects.
Management discussed strategic expansion and potential business development opportunities but offered no updated guidance or specific timelines to ease investor concerns.

View recap

Earnings Recaps

Autolus Therapeutics plc

Avax One Technology Ltd

Beam Global

Engine Gaming and Media, Inc.

Genmab A/S

Klarna Group plc

Lument Finance Trust, Inc.

PAVmed Inc.

Community

Earnings Recaps

Autolus Therapeutics plc

Avax One Technology Ltd

Beam Global

Engine Gaming and Media, Inc.

Genmab A/S

Klarna Group plc

Lument Finance Trust, Inc.

PAVmed Inc.

Community

Trending This Week

Notifications